breast feeding and glp 1 Thinking about GLP-1 support while breastfeeding? Watch this first 🩷🩷 Are GLP-1s safe for postpartum?

"GLP-1 receptor agonists and the risk of thyroid cancer." Diabetes Care

The candidate previously demonstrated promising weight loss outcomes in Phase 2 trials, and its progression into late-stage testing underscores the competitive momentum building in this high-growth therapeutic category In January 2024, Zealand Pharma and Boehringer Ingelheim announced positive Phase 2 results for BI 456906, a long-acting GLP-1/glucagon dual agonist, in obese individuals

Diagnostic evaluation of the infertile female: a committee opinion

But with its benefits often come a few unwelcome side effectsnausea, bloating, and constipation

This would help answer the question of whether previously reported negative outcomes in other trials were a drug-specific retinal toxicity of the GLP-1/GIP receptor agonists vs

The integration of IV nutrient therapy with conventional cancer treatment requires careful coordination and communication among all members of the healthcare team